England starts funding tirzepatide in primary care under phased obesity plan

England began a new stage of its obesity drug rollout on 23 June 2025, when Integrated Care Boards (ICBs) became required to fund tirzepatide (Mounjaro) in primary care for prioritized groups of patients ^[1]. The date is 180 days after NICE published final guidance on the drug, according to NHS England's interim commissioning guidance ^[1].

Tirzepatide is a dual GIP/GLP-1 receptor agonist that NICE recommends for managing obesity alongside a reduced-calorie diet and increased physical activity ^[1]. Funding in NHS specialist weight management services started earlier, on 24 March 2025 — 90 days after the guidance — and applies to the full eligible population, while the primary care mandate is being phased in ^[1].

The number of people covered at first is far smaller than the number who qualify. NICE's funding variation calls for an initial cohort of about 220,000 people over the first three years of delivery, covering 2025 to 2028 ^[1]. The full eligible population is estimated at 3.4 million, and NHS England says those patients should have access within a maximum of 12 years, based on prioritization led by clinical need ^[1]. NHS England describes the phase-in as a response to available capacity in primary care and says the early period will be used to evaluate and scale different service models ^[1].

Under NICE TA1026, adults qualify if they have an initial body mass index of at least 35 kg/m² and at least one weight-related condition. A lower BMI threshold is used for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, usually reduced by 2.5 kg/m² ^[1].

The guidance sets the rollout against the size of the problem in England: 29% of adults live with obesity and 64% live with overweight or obesity ^[1]. It cites NHS costs of about £11.4 billion a year from obesity, plus estimated wider societal costs of £74.3 billion a year, including lost productivity, unemployment and social care ^[1]. It also notes tirzepatide's status as a Black Triangle medicine and says its practical use outside clinical trials needs to be examined ^[1].

What has not been disclosed is how long an individual patient will wait, or which specific groups come first inside the phased primary care rollout. The published eligibility criteria apply the same BMI and comorbidity thresholds throughout the phase-in period ^[1]. The document is interim guidance, carrying a review date of 2 April 2026, with amendments from that review marked ^[1].

Why it matters for patients

The mandate applies to NHS-funded care in England ^[1]. It does not change coverage rules in the United States, where access to tirzepatide depends on insurers, employers and pharmacy benefit managers rather than a national health service.

The English approach is still a useful signal for anyone watching how large payers handle GLP-1 and dual-agonist obesity drugs. Rather than funding everyone who meets the clinical criteria at once, the NHS has narrowed the first three years to roughly 220,000 people, set a BMI threshold of at least 35 plus a related condition, and accepted that the remaining eligible patients may wait years ^[1]. The guidance says the limit reflects primary care capacity and the need to build service models, not a judgment that other patients would not benefit ^[1].

For patients in England, the practical effect is that meeting the criteria is necessary but not sufficient: eligibility expands in stages, and the point at which any given person can be funded has not been published ^[1]. For patients in the US, the specifics of the NHS rules do not apply, but the structure of the decision — eligibility rules, a fixed first-phase number, and a multi-year timeline — mirrors the questions US payers are weighing as demand for these drugs outpaces capacity.

What happens next

The dated milestones in the guidance are the specialist-service funding start on 24 March 2025 and the primary care funding start on 23 June 2025 ^[1]. The initial three-year implementation period runs from 2025 to 2028, building toward about 220,000 patients, with the full eligible population to be reached within 12 years ^[1]. The interim guidance was reviewed on 2 April 2026, and no schedule for expanding the priority cohorts beyond the current phase has been published ^[1].